Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Background: Immune checkpoint therapies are effective in the treatment of a subset of patients in many different cancers. Immunotherapy offers limited efficacy in part because of rapid drug clearance and off-target associated toxicity. PEG-PLGA is a FDA approved, safe, biodegradable polymer with fle...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Christina K., Atibalentja, Danielle F., Yao, Lilian E., Park, Jangho, Kuruvilla, Sibu, Felsher, Dean W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824669/
https://www.ncbi.nlm.nih.gov/pubmed/35145835
http://dx.doi.org/10.7150/ntno.65544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824669/
https://www.ncbi.nlm.nih.gov/pubmed/35145835
http://dx.doi.org/10.7150/ntno.65544

Ejemplares similares